What is Xencor's market cap?

Xencor (XNCR) has a market capitalization of $1.5B and trades on NASDAQ.

What is Xencor's revenue and profitability?

Xencor generated $97.4M in trailing twelve-month revenue with a net loss of $172.4M, representing a net margin of -177.1%, with free cash flow of -$188.8M. These figures are based on the Q1 2026 filing.

Who are Xencor's competitors?

Xencor's key competitors include Amgen, Regeneron Pharmaceuticals, AbCellera Biologics Inc. Common Shares, and others. These companies compete in similar markets and product categories.

Where is Xencor headquartered?

Xencor is headquartered in United States of America and employs approximately 280 people. It has been publicly traded since 2013.

Xencor

XNCR

Xencor is a clinical-stage biopharmaceutical company that utilizes proprietary protein engineering capabilities to develop engineered antibody therapeutics.

Market cap

$1.47B+137%

Revenue$97.4M-23.5%

Net income-$172.4M+16.9%

Free cash flow-$188.8M-11.8%

EPS (diluted)-$2.29+24.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$4.5MMiss by $23.3M EPS-$1.71Miss by $1.06

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$18.9M

EPS estimate-$0.84

Financials

Q1 2026

Income statement

See full

Revenue$4.5M-86.2%

Operating income-$77.9M-80.3%

Net income-$128.9M-166%

EPS (diluted)-$1.71-159%

Balance sheet

See full

Cash & equivalents$14.2M-64.3%

Total debt$175.2M-21.2%

Total equity$515.6M-19.4%

Total assets$736.8M-18.6%

Cash flow

See full

Operating cash flow-$67.6M-317%

CapEx$610.0K-57.8%

Free cash flow-$68.2M-286%

Valuation & ratios

Valuation

See full

Market cap$1.47B+137%

Enterprise value$1.63B+101%

P/S15.1×+10.7×

Profitability

See full

Operating margin-217.9%+425pp

Net margin-177.1%+16.5pp

FCF margin-194%+166pp

Returns & leverage

See full

Return on equity-29.8%-2.7pp

Debt / equity0.3×0.0×

Current ratio6.6×+0.7×

Competitors

By market cap

Amgen$203.07B+25.3%

Regeneron Pharmaceuticals$69.9B+16.0%

Xenon Pharmaceuticals$6.4B+168%

AbCellera Biologics Inc.$1.6B+9.2%

Xencor$1.5B+129%

Immix Biopharma, Inc.$618.6M+716%

Sutro Biopharma$397.9M+452%

Karyopharm Therapeutics$160.7M+326%

By revenue growth

AbCellera Biologics Inc.+243%

Sutro Biopharma+49.9%

Amgen+9.1%

Regeneron Pharmaceuticals+5.9%

Xencor-23.5%

Xenon Pharmaceuticals-100%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

Amgen20.96%+3.6pp

Sutro Biopharma-154.21%+215pp

Xencor-177.1%-13.9pp

AbCellera Biologics Inc.-181.75%+544pp

Xenon Pharmaceuticals-4,612.13%—

Profile

Xencor is a clinical-stage biopharmaceutical company that utilizes proprietary protein engineering capabilities to develop engineered antibody therapeutics. The company focuses on creating XmAb drug candidates with multi-target mechanisms of action and improved properties for the treatment of cancer and autoimmune diseases. By engineering the Fc domains of antibodies, Xencor designs scaffolds that enable bispecific structures and extended half-life for therapeutic candidates.

Competitive position

A leader in Fc domain engineering with a validated platform that has contributed to multiple marketed medicines.

GeographiesGlobal

Customer segmentsBiopharmaceutical companies, Oncology clinics, Specialty healthcare providers

Business modelR&D intensive, IP licensing, Royalty-based

SuppliersProtein engineering software, Laboratory equipment suppliers, Contract research organizations (CROs), Raw material suppliers for biologics

CustomersPharmaceutical licensing partners, Clinical trial sites, Specialty pharmacies

CountryUnited States of America

Listed2013

Employees280.0

CEOBassil I. Dahiyat

SectorHealthcare

IndustryBiotechnology

Websitexencor.com

FilingsSEC EDGAR

Ask your AI about Xencor.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xencor's market cap?: Xencor (XNCR) has a market capitalization of $1.5B and trades on NASDAQ.
What is Xencor's revenue and profitability?: Xencor generated $97.4M in trailing twelve-month revenue with a net loss of $172.4M, representing a net margin of -177.1%, with free cash flow of -$188.8M. These figures are based on the Q1 2026 filing.
Who are Xencor's competitors?: Xencor's key competitors include Amgen, Regeneron Pharmaceuticals, AbCellera Biologics Inc. Common Shares, and others. These companies compete in similar markets and product categories.
Where is Xencor headquartered?: Xencor is headquartered in United States of America and employs approximately 280 people. It has been publicly traded since 2013.